Back to search results

Observational Study of Immune Cell Response to Stimuli

This observational study is investigating how your immune cells (like neutrophils and monocytes) react to different signals in a test tube. Researchers want to understand how these cells sense signals in your body and what substances they produce in response. This will help them learn how immune cells might contribute to inflammation and how your blood responds to potential disease-related conditions. The study is looking for 750 healthy volunteers, aged 18 to 65, who weigh at least 110 pounds. You would need to be non-pregnant and test negative for HIV, Hepatitis B, and Hepatitis C. The study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 750 healthy adult participants.
What's involved
You would donate about 320 milliliters (about 1 1/3 cups) of blood no more frequently than once every 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00397280

Immune Cell Response to Stimuli

Recruiting
Not specifiedAges 18–65Observational
National Institute of Environmental Health Sciences (NIEHS)
~750 participants
Updated 2026-08-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The objective is to define the signaling pathways activated by lipopolysaccharide (LPS) and other selected innate immunity stimuli, and the downstream inflammatory functional consequences, in human leukocytes in vitro.
Measured over analysis of the study

Conditions

Inflammation

Explore related trials

InflammationInflammatory Response

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Michael B Fessler, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Environmental Health Sciences (NIEHS)

Who to contact

NIEHS Join A Study Recruitment Group
[email protected]
(855) 696-4347
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Normal, healthy adult donors as judged by screening questionnaire
Nonpregnant
Weighing at least 110 lbs
18-65 years of age
HIV negative (proof required every 6 months we will conduct test)\*
Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)\*
The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow

Exclusion

Hematocrit less than 34% for women or less than 36% for men, or greater than 56% for either gender.
Patients will be informed of disqualifying vital signs and hematocrit values and advised by trained staff, as appropriate, to seek assistance from their physician.

What this trial measures

  • The objective is to define the signaling pathways activated by lipopolysaccharide (LPS) and other selected innate immunity stimuli, and the downstream inflammatory functional consequences, in human leukocytes in vitro.analysis of the study

    The objective is to define the signaling pathways activated by lipopolysaccharide (LPS) and other selected innate immunity stimuli, and the downstream inflammatory functional consequences, in human leukocytes in vitro.